Abstract
SUMMARY INTRODUCTION:
Chronic daily headache is a high impact entity in the general population. Although chronic migraine and tension-type headache are the most frequent conditions, it is necessary to consider hemicrania continua and new daily persistent headache as part of the differential diagnoses to perform a correct therapeutic approach.
OBJECTIVE:
To make recommendations for the treatment of chronic daily headache of primary origin
METHODOLOGY:
The Colombian Association of Neurology, by consensus and Grade methodology (Grading of recommendations, assessment, development and evaluation), presents the recommendations for the preventive treatment of each of the entities of the daily chronic headache of primary origin group.
RESULTS:
For the treatment of chronic migraine, the Colombian Association of Neurology recommends onabotulinum toxin A, erenumab, topiramate, flunarizine, amitriptyline, and naratriptan. In chronic tension-type headache the recommended therapeutic options are amitriptyline, imipramine, venlafaxine and mirtazapine. Topiramate, melatonin, and celecoxib for the treatment of hemicrania continua. Options for new daily persistent headache include gabapentin and doxycycline. The recommendations for inpatient treatment of patients with chronic daily headache and the justifications for performing neural blockades as a therapeutic complement are also presented.
CONCLUSION:
The therapeutic recommendations for the treatment of chronic daily headache based on consensus methodology and Grade System are presented.
References
Schramm SH, Obermann M, Katsarava Z, Diener H-C, Moebus S, Yoon M-S. Epidemiological profiles of patients with chronic migraine and chronic tension-type headache. J Headache Pain [Internet]. 2013;14:2-8
Aliena M, Steiner TJ, Sances G, Carugno B, Balsamo F, Nappi G, et al. Impact of headache disorders in Italy and the public-health and policy implications : a population-based study within the Eurolight Project. J Headache Pain . 2015; 100:2-9
Stovner LJ, Andree C. Prevalence of headache in Europe: A review for the Eurolight project. J Headache Pain. 2010;11:289-99.
Vincent M, Wang S. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211.
Rodrigo A, Giacomozzi E, Vindas AP, Alberto A, Bordini A, Buonanotte CF, et al. Latin American consensus on guidelines for chronic migraine treatment. Arch Neurops. 2013;71:478-86.
Lupi C, Evangelista L, Favoni V, Granato A, Negro A, Pellesi L, et al. Rare primary headaches in Italian tertiary Headache Centres : Three year nationwide retrospective data from the RegistRare Network. Cephalalgia. 2018;0(0):1-13.
Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: A review of statistics from national surveillance studies. Headache. 2013;53:427-36.
Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563-78.
Buse DC, Manack a, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry [Internet]. 2010;81:428-32.
Fernández-Ávila DG, Rojas MX .El método Delphi en la investigación en reumatología: Lo estamos haciendo bien? Rev Colomb Reumatol. 2020;27(3):177-89.
Muñoz J, Volcy M, Sobrino F, Ramírez S, Uribe B. et al. Consenso de expertos de la Asociación Colombiana de Neurología para el tratamiento preventivo y agudo de la migraña. Acta Neurol Colomb. 2014;30(3):175-85.
Leone MA, Brainin M, Boon P, Pugliatti M, Keindl M, Bassetti CL. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations Eur J Neurol. 2012. 2013;410-9.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2 : a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions , or both. BMJ 2017;358:1-9.
Aurora SK, Dodick DW, Diener H-C, DeGryse RE, Turkel CC, Lipton RB, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerabik'ty in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand [Internet]. 2014;129:61-70.
Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804-14.
Dodick DW, Turkel CC, Degryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for Treatment of Chronic Migraine : Pooled Results From the Double-Blind , Randomized , Placebo-Controlled Phases of the PREEMPT Clinical Program. Headache.2010; 50:921-36
Diener H-C, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21:851-9.
Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Adams AM. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine : COMPEL study. J Headache Pain. 2018; 19:1-13
Herd CP, Tomlinson CL, Rick C, Scotton WJ , Edwards J, Ives N, et al. Botulinum toxins for the prevention of migraine in adults ( Review ). Cochranedata base Syst Rev 2018;(6). CD011616.
Silberstein SD, Dodick DW, Aurora SK, Diener H, Degryse RE, Lipton RB, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle : PREEMPT. J Neurol Neurosurg Psichiatry 2015;86: 996-1001
Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Articles Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised , double-blind , placebo-controlled phase 2 trial. Lancet Neurol. 2017; 16:425-434
Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, et al. Efficacy and safety of erenumab ( AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia.2018;0:1-11.
Barbanti P, Aurilia C, Egeo G, Fofi L. Erenumab : from scientific evidence to clinical practice - the first Italian real-life data. Neurol Sci. 2019;40:177-179
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine. Neurology.2018;0:2211-21.
Ruff DD, Ford JH, Tockhorn-heidenreich A, Sexson M, Govindan S, Pearlman EM, et al. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia.2019;39:931-44.
Ailani J, Perlman D, Zhang Q, Nagy A, Schuh K. Aurora S. Positive response to galcanezumab following treatment failure to onabotulinumtoxina in patients with migraine: Post hoc analyses of 3 randomized double-blind studies. Europ J Neurol. 2020; 27(3):542-9.
Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and galcanezumab in chronic migraine prevention : effects after treatment termination. J Headache Pain. 2019;20:1-5
Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Articles Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes ( FOCUS ): a randomised , double-blind , placebo-controlled , phase 3b trial. Lancet. 2019;6736:1-11
Goadsby PJ, Ph D, Blankenbiller T, Wolff MG, Yang R, Ph D, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Eng J Med. 2017;2113-22.
Bigal ME, Dodick DW, Abouch V, Vanderpluym JH, Tepper SJ, Aycardi E, et al. TEV-48125 for the preventive treatment of chronic migraine Efficacy at early time points. Neurology.2016;0:41-8.
Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, et al. Research Submission With Other Migraine Preventive Medicines. Headache. 2017;57(9):1375-1384
Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas D, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019 16;20:6
Robbins, L. Special report: CGRP monoclonal antibodies for chronic migraine. Pract Pain Manag 2019;19:45-52.
Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, et al. Eptinezumab for prevention of chronic migraine : A randomized phase 2b clinical trial. Cephalalgia. 2019;39:1075-85.
Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz R, A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina.Headache. 2018; 58:715-723
Hoon J De, Hecken A Van, Vandermeulen C, Herbots M, Kubo Y, Lee E, et al. to evaluate the effects of erenumab ( AMG 334 ) and concomitant sumatriptan on blood pressure in healthy volunteers. Cephalalgia.2018;0(0):100-110.
Robbins BL. At Stake : The Possible Long-Term Side Effects of CGRP Antagonists. Practical Pain Management. 2018 :1-10.
Melo-carrillo A, Strassman AM, Nir R, Schain XJ, Noseda XR, Stratton XJ, et al. Fremanezumab - A Humanized Monoclonal Anti-CGRP Antibody - Inhibits Thinly Myelinated (A V) But Not Unmyelinated ( C ) Meningeal Nociceptors. J Neurosci.2017;37:10587-96.
Silberstein SD, LIpton RB,Dodick DW,Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Greenberg D. Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine : A Randomized, Double-Blind ,Headache. 2007;170-80.
Diener H-C, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814-23.
Silberstein SD. Topiramate in Migraine Prevention : A 2016 Perspective. Headache.2016;57:165-178.
Cady RK, Schreiber CP, Porter J a H, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotu-linumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51:21-32.
Magalhães E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010;112:463-6.
Lai K, Fuh DMNJ, Chen S, Wang Y, Chen W, Wu J, et al. Flunarizine versus topiramate for chronic migraine prophylaxis : a randomized trial. Pain Med.2016;13:1-8.
Gracia-naya M, Ríos C, García-gomara MJ, Sánchez-valiente S, Maurillerda JA, Santos-lasaosa S, et al. Estudio comparativo de la efectividad del topiramato y la flunaricina en series independientes de pacientes con migraña crónica sin abuso de medicación. Rev Neurol.2013;57:347-53.
Blumenfeld AM, Schim JD, Chippendale TJ. Research Submission Botulinum Toxin Type A and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine. Headache. 2007;48:210-20.
Rapoport AM, Bigal ME, Volcy M, Sheftell FD, Feleppa M, Tepper SJ. Brief Communication Naratriptan in the Preventive Treatment of Refractory Chronic Migraine : A Review of 27 Cases. Headache. 2003;482-9.
Sheftell FD, Rapoport AM, Tepper SJ, Bigal ME. Naratriptan in the Preventive Treatment of Refractory Transformed Migraine : A Prospective Pilot Study. Headache. 2005;45:1400-6.
Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia. 2008;28:152-6.
Boe MG, Mygland A, Salvedsen R. Prednisolone does not reduce withdrawal headache. Neurology.2007;69:26-32.
Rabe K, Pageler L, Gaul C, Kraya T, Foerderreuther S, Diener H, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache : A randomized , double-blind , placebo-controlled study. Cephalalgia. 2012;33:202-7.
Taghdiri F, Togha M, Jahromi SR, Paknejad SMH. Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind clinical trial. Headache. 2015;55(1):128-35.
Krymchantowski A V, Moreira PF. Out-patient detoxification in chronic migraine : comparison of strategies. Cephalalgia.2003;:982-93.
Goffau MJ De, Klaver ARE, Willemsen MG, Bindels PJE, Verhagen AP. The effectiveness of treatments for patients with medication overuse headache; a systematic review and meta-analysis. J Pain. 2017; 8:615-627
Gobel H, Hamouz V, Hansen C, Heininger K, Hirsch S, Lindner V, et al. Chronic tension-type headache : amitriptyline reduces clinical headache-duration and experimental pain sensitivi ~ but does not alter pericranial muscle activity readings. Pain. 1994;59:241-9.
Pfaffenrath V, Diener H, Isler H, Meyer C, Scholz E, Taneri Z, et al. Efficacy and tolerability of amitriptylinoxide in the treatment of chronic tension-type headache : a multi-centre controlled study. Cephalalgia. 1994;14:8-14.
Bendtsen L, Jensen R, Olesen J. A non-selective ( amitriptyline ), but not a selective ( citalopram ), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psichitry. 1996;61:285-90.
Holroyd KA, Donnell FJO, Stensland M, Lipchik GL, Cordingley GE, Page P. Management of Chronic Tension-Type. JAMA.2001;285(17):2208-15.
Jackson JL, Mancuso JM, Nickoloff S, Bernstein R, Kay C. Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults : A Systematic Review and Meta-Analysis. J Gen Int Med.2017;1351-8.
Zissis NP, Harmoussi S, Vlaikidis N, Mitsikostas D, Thomaidis T, Georgiadis G, et al. A randomized , double-blind , placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia.2007;(8):315-24.
Mousavi Sayed Ali, Mousavi Mohossen FK. Comparison between efficacy of imipramine and transcutaneous electrical nerve stimulation in the prophylaxis of chronic tension-type headache: a randomized controlled clinical trial. J Res Med Sci. 2011;16:923-7.
Bendtsen L, Buchgreitz L, Ashina S, Jensen R. Combination of low-dose mirtazapine and ibuprofen for prophylaxis of chronic tension-type headache. Eur J Neurol.2007;187-93.
Sjastaad O. Evidence For A New ?, Treatable Headache Entity. Headache.1972;14:105-108.
Sjaastad O, Spierings ELH. " Hemicrania continua ": another headache absolutely responsive to indomethacin. Cephalalgia. 1984; 4:65-70
Pareja JA, Sjaastad O. Chronic Paroxysmal Hemicrania and Hemicrania Continua . Interval Between Indomethacin Administration and Response. Headache.1996;8-20-3
Rõ Ã, Pareja JA, Caminero AB, Franco E, Casado JL, Pascual J, et al. Dose , efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. Cephalalgia. 2001;(3):906-10.
Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain. 2010;133:1973-86.
Cortijo E, Guerrero-peral AL, Herrero-velázquez S, Mulero P, Pedraza M, Barón J, et al. Hemicránea continua : características y experiencia terapêutica en una serie de 36 pacientes. Neurologia. 2012;55(5):270-8.
Maria L, Rocha V, Marcelo J, Bezerra F, Regina N, Fleming P. Tratamiento de la Hemicránea Continua : Serie de Casos y Revisión de la Literatura. Rev Bras Anestesiol. 2012;62:173-187.
Spears R. Hemicrania Continua: A Case in Which A Patient Experienced Complete Relief on Melatonin. Headache. 2006;46: 524-27
Rozen TD. Melatonin Responsive Hemicrania Continua. Headache. 2006;46:1203-9.
Hollingworth M, Young TM. Melatonin Responsive Hemicrania Continua in Which Indomethacin Was Associated With Contralateral Headache. 2014;54: 916-9
Rozen TD. How Effective Is Melatonin as a Preventive Treatment for Hemicrania Continua ? A Clinic-Based Study Headache. 2015;55:430-6.
Matharu MS, Bradbury P, Swash M. Hemicrania continua : side alternation and response to topiramate. Cephalalgia.2005; 26-341-344
Brighina F, Palermo A, Cosentino G, Fierro B. Prophylaxis of hemicrania continua: Two new cases effectively treated with topiramate. Headache. 2007;47:441-43.
Prakash S. Rana K. Clinical Correspondence Topiramate as an Indomethacin-Sparing Agent in Hemicrania Continua : A Report of 2 Cases. Headache. 2019;59:1-2.
Peres M. Silberstein SD. Hemicrania Continua Responds to to Cyclooxygenase-2 Inhibitors. Headache. 2002;530-1.
Porta-Etessam J. Cuadrado P, Valencia C. Are Cox-2 drugs the second line option in indomethacin responsive headaches ? J Headache Pain. 2010;405-7.
Nierenburg H, Newman LC. Update on New Daily Persistent Headache. Curr Treat Options Neurol . 2016; 18:25
Rozen TD. New Daily Persistent Headache : An Update. Curr Pain Headache Rep. 2014; 18:431
Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH. Ketorolac in the treatment of acute migraine: a systematic review. Headache. 2013;53:277-87.
Domi R. The intravenous administration of ketoprofene : a suitable alternative for acute postoperative pain management in developing countries. Clin J Pain. 2004;20(3):198.
Friedman BW, Garber L, Yoon A, Solorzano C, Wollowitz A, Esses D, et al. Randomized trial of IV valproate vs meto-clopramide vs ketorolac for acute migraine. Neurology . 2014;82:976-83.
Ramanioccti As, Soares B, Atallah A. Dipyrone for acute primary headaches ( Review ). Cochrane Database Syst Rev 2014;(7). CD004842.
Soleimanpour H, Rajaei Ghafouri R, Taheraghdam A, Aghamo-hammadi D, Negargar S, Golzari SE, et al. Effectiveness of intravenous Dexamethasone versus propofol for pain relief in the migraine headache: a prospective double blind randomized clinical trial. BMC Neurol. 2012;12:2-7
Foroughipour M, Ghandehari K, Khazaei M, Ahmadi F, Shariatinezhad K. Randomized clinical trial of intravenous valproate (orifil) and dexamethasone in patients with migraine disorder. Iran JMedSci. 2013;38:150-5.
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012;52:292-306.
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium. Headache . 2012;52:114-28.
Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches-- a narrative review. Headache. 2013;53:437-46.
Hascalovici JR, Robbins MS. Research Submission Peripheral Nerve Blocks for the Treatment of Headache in Older Adults : A Retrospective Study. Headache. 2017;57:80-6.
Gul HL, Ozon AO, Karadas O, Koc G, Inan LE. The efficacy of greater occipital nerve blockade in chronic migraine : A placebo- controlled study. Acta Neurol Scand. 2016;136:1-7.
Young W Cook B, Malik S, Shaw J, Oshinski M. The First 5 Minutes After Greater Occipital Nerve BlockHeadache. 2014;48(7):1126-8.
Cady RK, Saper J, Dexter K, Cady RJ, Manley HR. Randomized Study for Repetitive Sphenopalatine Blockade With Bupiva-caine vs Saline With the Tx360 ® Device for Treatment of Chronic Migraine. Headache. 2015; 55:101-116
Guerrero L, Herrero-vela S, Pen L, Pedraza I, Cortijo E, Mulero P, et al. Peripheral nerve blocks : a therapeutic alternative for hemicrania continua. J Headache Pain. 2012;32(6):505-8.
Androulakis XM, Krebs KA, Ashkenazi A. Hemicrania continua may respond to repetitive sphenopalatine ganglion block: A case report Headache. 2016; 56:573-579.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.